{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:05:22Z","timestamp":1787069122247,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","award":["2021-2022"],"award-info":[{"award-number":["2021-2022"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018701","name":"HORIZON EUROPE Food, Bioeconomy, Natural Resources, Agriculture and Environment","doi-asserted-by":"publisher","award":["101059924"],"award-info":[{"award-number":["101059924"]}],"id":[{"id":"10.13039\/100018701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013890","name":"Ministerie van Landbouw, Natuur en Voedselkwaliteit","doi-asserted-by":"publisher","award":["WOT-01-002-041"],"award-info":[{"award-number":["WOT-01-002-041"]}],"id":[{"id":"10.13039\/501100013890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.vaccine.2025.127772","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T06:53:54Z","timestamp":1758696834000},"page":"127772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Development of African horse sickness disabled infectious single animal (DISA)-DIVA vaccine platform applied for all nine serotypes"],"prefix":"10.1016","volume":"64","author":[{"given":"Piet A.","family":"van Rijn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Wernery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arno-Jan","family":"Feddema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke A.","family":"Maris-Veldhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunitha","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 G.P.","family":"van Gennip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127772_bb0005","series-title":"Encyclopedia of virology","first-page":"17","article-title":"African horse sickness","author":"van Rijn","year":"2021"},{"key":"10.1016\/j.vaccine.2025.127772_bb0010","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/vr.101083","article-title":"Outbreaks of African horse sickness in Senegal, and methods of control of the 2007 epidemic","volume":"172","author":"Diouf","year":"2013","journal-title":"Vet. Rec."},{"key":"10.1016\/j.vaccine.2025.127772_bb0015","first-page":"26","article-title":"African horsesickness and the epizootic in Spain 1987","volume":"10","author":"Lubroth","year":"1988","journal-title":"Equine Pract"},{"key":"10.1016\/j.vaccine.2025.127772_bb0020","first-page":"1751","article-title":"African horse sickness: its emergence in Thailand and potential threat to other Asian countries","volume":"67","author":"Lu","year":"2020","journal-title":"Transbound. Emerg. Dis."},{"key":"10.1016\/j.vaccine.2025.127772_bb0025","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001782","article-title":"ICTV virus taxonomy profile: Sedoreoviridae 2022","volume":"103","author":"Matthijnssens","year":"2022","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2025.127772_bb0030","first-page":"7","article-title":"The transmission of bluetongue and horsesickness by Culicoides","volume":"19","author":"Du Toit","year":"1944","journal-title":"Onderstepoort J Vet Anim Ind"},{"key":"10.1016\/j.vaccine.2025.127772_bb0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1365-2915.2000.00245.x","article-title":"African horse sickness epidemiology: vector competence of south african Culicoides species for virus serotypes 3, 5 and 8","volume":"14","author":"Venter","year":"2000","journal-title":"Med. Vet. Entomol."},{"key":"10.1016\/j.vaccine.2025.127772_bb0040","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1046\/j.1365-2915.1998.00116.x","article-title":"Vector competence of Culicoides bolitinos and C. Imicola for south African bluetongue virus serotypes 1, 3 and 4","volume":"12","author":"Venter","year":"1998","journal-title":"Med. Vet. Entomol."},{"key":"10.1016\/j.vaccine.2025.127772_bb0045","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1051\/vetres:2004021","article-title":"African horse sickness","volume":"35","author":"Mellor","year":"2004","journal-title":"Vet. Res."},{"key":"10.1016\/j.vaccine.2025.127772_bb0050","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3201\/eid2212.160718","article-title":"African horse sickness caused by genome Reassortment and reversion to virulence of live, attenuated vaccine viruses, South Africa, 2004-2014","volume":"22","author":"Weyer","year":"2016","journal-title":"Emerg. Infect. Dis."},{"issue":"Pt 9","key":"10.1016\/j.vaccine.2025.127772_bb0055","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1099\/0022-1317-77-9-2053","article-title":"Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge","volume":"77","author":"Roy","year":"1996","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2025.127772_bb0060","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0264-410X(01)00445-5","article-title":"The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant","volume":"20","author":"Scanlen","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127772_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016503","article-title":"A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR \u2212\/\u2212 mouse model","volume":"6","author":"Castillo-Olivares","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127772_bb0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.virusres.2013.12.002","article-title":"Vaccination of mice with a modified vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation","volume":"180","author":"Calvo-Pinilla","year":"2014","journal-title":"Virus Res."},{"key":"10.1016\/j.vaccine.2025.127772_bb0075","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.vetimm.2012.06.009","article-title":"An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses","volume":"149","author":"El Garch","year":"2012","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.vaccine.2025.127772_bb0080","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1016\/j.vaccine.2014.04.036","article-title":"Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge","volume":"32","author":"Alberca","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127772_bb0085","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/evj.13363","article-title":"Humoral antibody response of 10 horses after vaccination against African horse sickness with an inactivated vaccine containing all 9 serotypes in one injection","volume":"53","author":"Wernery","year":"2021","journal-title":"Equine Vet. J."},{"key":"10.1016\/j.vaccine.2025.127772_bb0090","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.vaccine.2018.03.003","article-title":"African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3\/NS3a protein is not virulent and a safe promising AHS disabled infectious single animal (DISA) vaccine platform","volume":"36","author":"van Rijn","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127772_bb0095","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1016\/j.vaccine.2017.06.023","article-title":"Protective efficacy of multivalent replication-abortive vaccine strains in horses against African horse sickness virus challenge","volume":"35","author":"Lulla","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127772_bb0100","doi-asserted-by":"crossref","first-page":"7108","DOI":"10.1016\/j.vaccine.2020.08.072","article-title":"Safety and efficacy of inactivated African horse sickness (AHS) vaccine formulated with different adjuvants","volume":"38","author":"van Rijn","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127772_bb0105","doi-asserted-by":"crossref","first-page":"10213","DOI":"10.1128\/JVI.05412-11","article-title":"Generation of replication-defective virus-based vaccines that confer full protection in sheep against virulent bluetongue virus challenge","volume":"85","author":"Matsuo","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2025.127772_bb0110","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.vaccine.2014.12.003","article-title":"Application of bluetongue disabled infectious single animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2","volume":"33","author":"Feenstra","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127772_bb0115","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3389\/fvets.2019.00407","article-title":"Prospects of next-generation vaccines for bluetongue","volume":"6","author":"van Rijn","year":"2019","journal-title":"Front Vet Sci"},{"key":"10.1016\/j.vaccine.2025.127772_bb0120","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1016\/j.vaccine.2015.09.020","article-title":"Development of a competitive ELISA for NS3 antibodies as DIVA test accompanying the novel disabled infectious single animal (DISA) vaccine for bluetongue","volume":"33","author":"Tacken","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127772_bb0125","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.vetmic.2009.01.033","article-title":"A DIVA system based on the detection of antibodies to non-structural protein 3 (NS3) of bluetongue virus","volume":"137","author":"Barros","year":"2009","journal-title":"Vet. Microbiol."},{"key":"10.1016\/j.vaccine.2025.127772_bb0130","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1016\/j.vaccine.2013.08.089","article-title":"Bluetongue virus with mutated genome segment 10 to differentiate infected from vaccinated animals: a genetic DIVA approach","volume":"31","author":"van Rijn","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127772_bb0135","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01892-16","article-title":"Replication-deficient particles: new insights into the next generation of bluetongue virus vaccines","volume":"91","author":"Celma","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2025.127772_bb0140","first-page":"9","article-title":"Pentavalent disabled infectious single animal (DISA)\/DIVA vaccine provides protection in sheep and cattle against different serotypes of bluetongue virus","author":"van Rijn","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127772_bb0145","doi-asserted-by":"crossref","first-page":"8241","DOI":"10.1128\/JVI.00678-13","article-title":"NS3 of bluetongue virus interferes with the induction of type I interferon","volume":"87","author":"Chauveau","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2025.127772_bb0150","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.vaccine.2023.12.028","article-title":"Identification of T cell and linear B cell epitopes on African horse sickness virus serotype 4 proteins VP1-1, VP2, VP4, VP7 and NS3","volume":"42","author":"Faber","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127772_bb0155","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.virusres.2016.04.007","article-title":"African horse sickness virus serotype 4 antigens, VP1-1, VP2-2, VP4, VP7 and NS3, induce cytotoxic T cell responses in vitro","volume":"220","author":"Faber","year":"2016","journal-title":"Virus Res."},{"key":"10.1016\/j.vaccine.2025.127772_bb0160","doi-asserted-by":"crossref","first-page":"1440407","DOI":"10.3389\/fimmu.2024.1440407","article-title":"Co-expression of VP2, NS1 and NS2-Nt proteins by an MVA viral vector induces complete protection against bluetongue virus","volume":"15","author":"Jim\u00e9nez-Cabello","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vaccine.2025.127772_bb0165","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1016\/j.vaccine.2018.05.044","article-title":"Diagnostic DIVA tests accompanying the disabled infectious single animal (DISA) vaccine platform for African horse sickness","volume":"36","author":"van Rijn","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127772_bb0170","doi-asserted-by":"crossref","first-page":"8764","DOI":"10.1128\/JVI.01052-15","article-title":"VP2 exchange and NS3\/NS3a deletion in African horse sickness virus (AHSV) in development of disabled infectious single animal vaccine candidates for AHSV","volume":"89","author":"van de Water","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2025.127772_bb0175","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF01314778","article-title":"Persistent infection of BHK21\/WI-2 cells with rubella virus and characterization of rubella variants","volume":"54","author":"Sato","year":"1977","journal-title":"Arch. Virol."},{"key":"10.1016\/j.vaccine.2025.127772_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030540","article-title":"Rescue of recent virulent and avirulent field strains of bluetongue virus by reverse genetics","volume":"7","author":"van Gennip","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127772_bb0185","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1006\/viro.1999.9680","article-title":"Antigenic profile of African horse sickness virus serotype 4 VP5 and identification of a neutralizing epitope shared with bluetongue virus and epizootic hemorrhagic disease virus","volume":"257","author":"Martinez-Torrecuadrada","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2025.127772_bb0190","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.1016\/j.vaccine.2014.07.031","article-title":"Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus","volume":"32","author":"Kanai","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127772_bb0195","doi-asserted-by":"crossref","DOI":"10.3201\/eid3008.231331","article-title":"Emergence of bluetongue virus serotype 3, the Netherlands, September 2023","volume":"30","author":"Holwerda","year":"2024","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.vaccine.2025.127772_bb0200","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jviromet.2019.05.002","article-title":"PCR diagnostics: in silico validation by an automated tool using freely available software programs","volume":"270","author":"van Weezep","year":"2019","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.vaccine.2025.127772_bb0205","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s10096-008-0556-9","article-title":"The development of a qualitative real-time RT-PCR assay for the detection of hepatitis C virus","volume":"27","author":"Clancy","year":"2008","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.vaccine.2025.127772_bb0210","first-page":"221","article-title":"Molecular epidemiology of African horse sickness virus based on analyses and comparisons of genome segments 7 and 10","volume":"14","author":"Zientara","year":"1998","journal-title":"Arch. Virol. Suppl."},{"key":"10.1016\/j.vaccine.2025.127772_bb0215","doi-asserted-by":"crossref","first-page":"7405","DOI":"10.1128\/JVI.00548-16","article-title":"Assembly of replication-incompetent African horse sickness virus particles: rational Design of Vaccines for all serotypes","volume":"90","author":"Lulla","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2025.127772_bb0220","series-title":"The pathogenesis of African Horsesickness. Proceedings of the 3rd Int Conf Equine Infectious Diseases. Paris: Karger, Basel","first-page":"1","author":"Erasmus","year":"1973"},{"key":"10.1016\/j.vaccine.2025.127772_bb0225","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/s13071-019-3722-2","article-title":"Vector competence is strongly affected by a small deletion or point mutations in bluetongue virus","volume":"12","author":"van Gennip","year":"2019","journal-title":"Parasit. Vectors"},{"key":"10.1016\/j.vaccine.2025.127772_bb0230","doi-asserted-by":"crossref","first-page":"12222","DOI":"10.1128\/JVI.02183-14","article-title":"A synthetic biology approach for a vaccine platform against known and newly emerging serotypes of bluetongue virus","volume":"88","author":"Nunes","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2025.127772_bb0235","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0168-1702(95)00061-T","article-title":"The use of African horse sickness virus NS3 protein, expressed in bacteria, as a marker to differentiate infected from vaccinated horses","volume":"38","author":"Laviada","year":"1995","journal-title":"Virus Res."},{"key":"10.1016\/j.vaccine.2025.127772_bb0240","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/tbed.12100","article-title":"Bluetongue virus RNA detection by real-time rt-PCR in post-vaccination samples from cattle","volume":"62","author":"De Leeuw","year":"2015","journal-title":"Transbound. Emerg. Dis."},{"key":"10.1016\/j.vaccine.2025.127772_bb0245","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1016\/j.vaccine.2010.06.034","article-title":"Bluetongue virus RNA detection by RT-qPCR in blood samples of sheep vaccinated with a commercially available inactivated BTV-8 vaccine","volume":"28","author":"Steinrigl","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127772_bb0250","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s12917-020-02540-y","article-title":"Immune response of horses to inactivated African horse sickness vaccines","volume":"16","author":"Rodr\u00edguez","year":"2020","journal-title":"BMC Vet. Res."}],"updated-by":[{"DOI":"10.1016\/j.vaccine.2025.127839","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000}}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25010692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25010692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:52:45Z","timestamp":1769025165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25010692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":50,"alternative-id":["S0264410X25010692"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127772","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of African horse sickness disabled infectious single animal (DISA)-DIVA vaccine platform applied for all nine serotypes","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127772"}}